Cargando…
Do patients with soft-tissue sarcomas treated with trabectedin have better clinical effects and a longer survival time than those treated with doxorubicin?
Autores principales: | Wu, Jiangfeng, Zhang, Maoliang, Chen, Chunting, Zhao, Anli, Guo, Yinghong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9073773/ https://www.ncbi.nlm.nih.gov/pubmed/35530946 http://dx.doi.org/10.21037/atm-21-7018 |
Ejemplares similares
-
Comparison between trabectedin and doxorubicin in soft-tissue sarcomas-reply letter
por: Dang, Jing-Yi, et al.
Publicado: (2022) -
Trabectedin in Soft Tissue Sarcomas
por: Petek, Bradley J., et al.
Publicado: (2015) -
Trabectedin for soft tissue sarcoma
Publicado: (2021) -
The Role of Trabectedin in Soft Tissue Sarcoma
por: Nakamura, Tomoki, et al.
Publicado: (2022) -
Comparison between trabectedin and doxorubicin in soft-tissue sarcomas: a systematic review and meta-analysis
por: Dang, Jingyi, et al.
Publicado: (2021)